Dinutuximab: A Review in High-Risk Neuroblastoma

Targeted Oncology
Sheridan M Hoy

Abstract

Dinutuximab (ch14.18; Unituxin™) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma. In a multinational, phase III study in this patient population, event-free survival (EFS) benefits with the dinutuximab-containing regimen versus isotretinoin alone were observed at the time of the primary (p = 0.0115) and confirmatory (p = 0.0330) efficacy analyses, although the observed p-value for the between-group difference in EFS for the primary efficacy analysis did not cross the prespecified boundary for statistical significance (p < 0.0108). Significant and sustained (5 years) overall survival benefits were seen with the dinutuximab-containing regimen versus isotretinoin alone. Despite pretreatment with analgesics, antihistamines and antipyretics, serious adverse reactions have been reported with the dinutuximab-containing regimen, with infusion reactions and neuropathy pro...Continue Reading

References

Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R HandgretingerD Neithammer
Jun 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A L YuF H Kung
Jun 19, 2010·The New England Journal of Medicine·John M Maris
Oct 1, 2010·The New England Journal of Medicine·Alice L YuUNKNOWN Children's Oncology Group
Feb 7, 2013·The Annals of Pharmacotherapy·Kerry ParsonsBrandy Strickland
Sep 13, 2014·Cancer Chemotherapy and Pharmacology·Ami V DesaiFrank M Balis
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Navin R PintoSusan L Cohn

❮ Previous
Next ❯

Citations

Sep 27, 2016·Toxins·Bryan D Fleming, Mitchell Ho
Feb 1, 2017·Immunology and Cell Biology·Maria Carmen OchoaPedro Berraondo
Jan 10, 2018·Frontiers in Immunology·Isabel Corraliza-GorjónLeonor Kremer
Dec 13, 2019·Cancer Metastasis Reviews·Brian HutzenTimothy P Cripe
Oct 20, 2017·Frontiers in Immunology·Michael J E MarshallMark S Cragg
Mar 15, 2019·FEBS Open Bio·Guojin XieYong Chang
Sep 29, 2019·Pharmacological Reviews·Peter J Houghton, Raushan T Kurmasheva
Dec 1, 2020·Journal of Biomedical Materials Research. Part a·Kimberly J OrnellJeannine M Coburn
Dec 18, 2020·Frontiers in Oncology·Alex J PootMax M van Noesel
Oct 30, 2020·Frontiers in Cell and Developmental Biology·Monica PhimmachanhDavid R Croucher
Jul 31, 2021·Molecular Diagnosis & Therapy·Shee Kwan PhungMartin Felices
Aug 7, 2021·International Reviews of Immunology·Divya Kandari, Rakesh Bhatnagar

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.